Skip to content
Screener

Ironwood Pharmaceuticals IRWD Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$106.5MBeat by $14.4M
EPS$0.24Beat by $0.17
Revenue estimate$92.1M
EPS estimate$0.07

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$120.0M
EPS estimate$0.30

Financials

Q1 2026

Income statement

See full
Revenue$106.5M+159%
Operating income$72.6M+349%
Net income$40.8M+209%
EPS (diluted)$0.24+204%

Balance sheet

See full
Cash & equivalents$220.5M+103%
Total debt$212.4M+1,323%
Total equity-$217.1M+35.0%
Total assets$434.6M+32.8%

Cash flow

See full
Operating cash flow$5.1M-74.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$572.33M+143%
Enterprise value$564.22M+298%
P/E5.6×—
P/S1.6×+0.8×

Profitability

See full
Operating margin55.4%+38.7pp
Net margin28.3%+22.3pp

Returns & leverage

See full
Current ratio1.4×-1.9×

Segments

By product

See full
Royalty$800.0K0.0%
Collaborative Arrangement Development And Commercialization Agreements$200.0K-60.0%

FAQ

When did Ironwood Pharmaceuticals report Q1 2026 earnings?
Ironwood Pharmaceuticals (IRWD) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Ironwood Pharmaceuticals's Q1 2026 revenue and EPS?
Ironwood Pharmaceuticals reported revenue of $106.5M and eps of $0.24 for Q1 2026.
Did Ironwood Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $92.1M by $14.4M. EPS beat the consensus estimate of $0.07 by $0.17.
How did Ironwood Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 158.9% from $41.1M a year earlier.
Where can I find Ironwood Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-056656) and the 10-Q periodic report (0001104659-26-057110) directly on SEC EDGAR. The filing index links above go to sec.gov.